Adage Capital Partners’s Kura Oncology KURA Stock Holding History

Adage Capital Partners’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-425,000	Closed	-$5.81M	–	1017
2022 Q3	$5.81M	Sell	425,000 -25,000	-6%	-$386K	0.01%	759
2022 Q2	$8.25M	Buy	450,000 +200,000	+80%	+$2.88M	0.02%	716
2022 Q1	$4.02M	Buy	+250,000	New	+$3.61M	0.01%	853
2020 Q4	–	Sell	-1,500,450	Closed	-$46M	–	857
2020 Q3	$46M	Sell	1,500,450 -309,000	-17%	-$6.82M	0.12%	190
2020 Q2	$29.5M	Buy	1,809,450 +1,259,450	+229%	+$18.2M	0.08%	292
2020 Q1	$5.47M	Buy	550,000 +500,000	+1,000%	+$5.72M	0.02%	564
2019 Q4	$688K	Hold	50,000	–	–	﹤0.01%	686
2019 Q3	$759K	Hold	50,000	–	–	﹤0.01%	692
2019 Q2	$985K	Hold	50,000	–	–	﹤0.01%	680
2019 Q1	$830K	Buy	+50,000	New	+$770K	﹤0.01%	663

Other funds holding KURA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Adage Capital Partners's KURA Position: Q4 2022 in Review

Adage Capital Partners sold out of Kura Oncology (KURA) in Q4 2022, closing a stake of 425,000 shares — an estimated $5.81M sold.

Adage Capital Partners first reported a position in KURA in Q1 2019 and held it in 10 quarters. The position peaked at $46M in Q3 2020. 142 funds tracked by Wall St. Rank hold KURA as of Q4 2022.

Adage Capital Partners reported no remaining Kura Oncology position as of Q4 2022 after selling out during the quarter.
Adage Capital Partners sold 425,000 Kura Oncology shares in Q4 2022, an estimated $5.81M.
Adage Capital Partners first reported a position in Kura Oncology in Q1 2019 and held it in 10 quarters.
Adage Capital Partners's Kura Oncology position peaked at $46M in Q3 2020.
142 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2022.

Based on Adage Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.